TY - JOUR
T1 - Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction
AU - Gutstein, David E.
AU - Fuster, Valentin
PY - 1998
Y1 - 1998
N2 - Postmyocardial infarction (MI) survival has been steadily improving. This improvement has been due, in part, to the actions of the adjunctive medical therapies for the treatment of MI. Aspirin, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and lipid-lowering agents have been shown to improve survival in the treatment and secondary prevention of MI. Nitrates have beneficial effects as well. These medications complement the reperfusion strategies through different mechanisms. Other adjunctive medical therapies, namely magnesium, antiarrhythmic agents, and calcium- channel blockers, have not been shown to improve mortality with routine post- MI use despite their theoretical benefits.
AB - Postmyocardial infarction (MI) survival has been steadily improving. This improvement has been due, in part, to the actions of the adjunctive medical therapies for the treatment of MI. Aspirin, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and lipid-lowering agents have been shown to improve survival in the treatment and secondary prevention of MI. Nitrates have beneficial effects as well. These medications complement the reperfusion strategies through different mechanisms. Other adjunctive medical therapies, namely magnesium, antiarrhythmic agents, and calcium- channel blockers, have not been shown to improve mortality with routine post- MI use despite their theoretical benefits.
KW - Adjunctive medical therapy
KW - Myocardial infarction
KW - Pathophysiology
KW - Secondary prevention
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=0031912292&partnerID=8YFLogxK
U2 - 10.1002/clc.4960210305
DO - 10.1002/clc.4960210305
M3 - Review article
C2 - 9541759
AN - SCOPUS:0031912292
SN - 0160-9289
VL - 21
SP - 161
EP - 168
JO - Clinical Cardiology
JF - Clinical Cardiology
IS - 3
ER -